ALS Drug Gets FDA Panel Thumbs Up After Rare Second Look

An FDA advisory panel reversed its March decision to reject a novel drug for ALS, citing persuasive new evidence and clinician support.

Related Keywords

Baltimore ,Maryland ,United States ,Phoenix ,Arizona ,Canada ,Tammy Sarnelli ,Justin Klee ,Teresa Buracchio ,Emily Freilich ,Caleb Alexander ,Billy Dunn ,Indiana University School Of Medicine ,Central Nervous System Drugs Advisory Committee ,Drug Association ,Office Of Neuroscience ,Amylyx Pharmaceuticals ,Division Of Neurology ,Alzheimer Disease Research ,Regulatory Affairs For Amylyx ,Medscape Medical News ,Distinguished Professor ,Peer Baekgaard Chair ,Disease Research ,Indiana University School ,Johns Hopkins Bloomberg School ,Public Health Center ,Drug Safety ,Regulatory Affairs ,Amyotrophic Lateral Sclerosis ,Ls ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Clinical Research ,Clinical Trials ,Linical Studies ,Medical Literature ,Books ,Textbooks ,Ournals ,